Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Prostatic Hyperplasia/drug therapy"'
Autor:
Danielle Kerkhofs, Robin Helgers, Denise Hermes, Hellen P.J. Steinbusch, Helma Van Essen, Peter Leenders, Jos Prickaerts, Julie Staals, Erik A. Biessen, Robert J. Van Oostenbrugge, Sébastien Foulquier
Publikováno v:
Journal of Hypertension. 41(7):1159-1167
BACKGROUND: SBP and blood pressure variability are independent risk factors for cerebral small vessel disease, a leading cause for stroke and dementia. Calcium-channel blockers are known to reduce blood pressure variability and may thus offer benefit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::218cccbd589fa021577764eeaded438a
https://doi.org/10.1097/HJH.0000000000003445
https://doi.org/10.1097/HJH.0000000000003445
Autor:
Che-Hsueh Yang, Yen-Chuan Ou, Chi-Chien Lin, Yi-Sheng Lin, Min-Che Tung, Chia-Cheng Yu, Jen-Tai Lin, Chen-Yueh Wen
Publikováno v:
Life, Vol 12, Iss 7, p 1029 (2022)
Currently, medication for benign prostate hyperplasia (BPH) and prostate cancer (PCa) are mainly based on modulating the hormone and nervous systems. However, side effects often affect patients, and might decrease their commitment to continuing the m
Externí odkaz:
https://doaj.org/article/a660796e31f24bbb9d99f6eaf70eac13
Publikováno v:
Bengtsen, M B, Heide-Jørgensen, U, Borre, M & Nørgaard, M 2023, ' Long-term risk of benign prostatic hyperplasia-related surgery and acute urinary retention in men treated with 5-alpha reductase inhibitor versus alpha-blocker monotherapy in routine clinical care ', The Prostate, vol. 83, no. 10, pp. 980-989 . https://doi.org/10.1002/pros.24540
OBJECTIVES: To assess the risk of benign prostatic hyperplasia (BPH)-related surgery and acute urinary retention (AUR) in men treated with 5-alpha-reductase inhibitor (5-ARI) versus alpha-blocker monotherapy in routine clinical care over 15 years of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31f52de113dccdc73773361be98ab40e
https://pure.au.dk/portal/da/publications/longterm-risk-of-benign-prostatic-hyperplasiarelated-surgery-and-acute-urinary-retention-in-men-treated-with-5alpha-reductase-inhibitor-versus-alphablocker-monotherapy-in-routine-clinical-care(f7c1d1a6-51f1-4c09-af10-a1fca54c6cc6).html
https://pure.au.dk/portal/da/publications/longterm-risk-of-benign-prostatic-hyperplasiarelated-surgery-and-acute-urinary-retention-in-men-treated-with-5alpha-reductase-inhibitor-versus-alphablocker-monotherapy-in-routine-clinical-care(f7c1d1a6-51f1-4c09-af10-a1fca54c6cc6).html
Autor:
Idris Guessous, Chiranjeev Dash
Publikováno v:
Journal of General Internal Medicine, Vol. 30, No 4 (2015) pp. 392-4
A nyone traveling to the United States from countries other than New Zealand will be surprised by the prevalence of health-related advertisements on television, including ads for drugs. Typically, these TV ads follow a pattern: an ad for a burger at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a47c104dcae46cb8cf9d03ba194874ca
https://doi.org/10.1007/s11606-015-3187-8
https://doi.org/10.1007/s11606-015-3187-8
Autor:
Maxime Rossi, Thierry Roumeguere
Publikováno v:
Drug Design, Development and Therapy, Vol 2010, Iss default, Pp 291-297 (2010)
Drug Design, Development and Therapy
Drug Design, Development and Therapy, 4
Drug Design, Development and Therapy
Drug Design, Development and Therapy, 4
Benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) are highly prevalent in older men. Medical therapy is the first-line treatment for LUTS due to BPH. Alpha-adrenergic receptor blockers remain one of the mainstays in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f29faf31da65810231ebb02d901e73b
http://www.dovepress.com/silodosin-in-the-treatment-of-benign-prostatic-hyperplasia-a5558
http://www.dovepress.com/silodosin-in-the-treatment-of-benign-prostatic-hyperplasia-a5558
Publikováno v:
泌尿器科紀要. 49(9):509-514
前立腺肥大症に対する八味地黄丸の少量2週間投与による治療成績を検討した.対象は, 前立腺肥大症で前治療を受けていない41名(平均年齢65.2歳)で, 八味地黄丸エキス剤1日4.0gを2週間投与
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=jairo_______::3563dbf526eed085c9306b5a22246a50
http://hdl.handle.net/2433/115048
http://hdl.handle.net/2433/115048
Publikováno v:
泌尿器科紀要. 48(5):269-273
尿障害を訴える前立腺肥大症患者129例を対象とし, アリルエストレノール50mg/dayによる内服治療を16週間行い, アリルエストレノールの治療効果と薬剤の安全性を多施設共同研究として検
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=jairo_______::75e66c9df1b9deeecef9b88e281004d5
http://hdl.handle.net/2433/114757
http://hdl.handle.net/2433/114757
Publikováno v:
泌尿器科紀要. 37(1):99-103
1988年2月からの約3ヵ月間にTURを受けた71例中肝腎に異常のない48例を対象とした.尿中の細菌消失日数はOFLX長期投与群が対照に比しやや短縮したが統計学的に有意差ではなかった
The pre
The pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=jairo_______::aaf446262bc2387c0ec8087d44621781
http://hdl.handle.net/2433/117079
http://hdl.handle.net/2433/117079
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.